Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin

[1]  E. Gronda,et al.  Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial". , 2022, Circulation.

[2]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[3]  Sanjiv J. Shah,et al.  The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial , 2021, Nature Medicine.

[4]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[5]  G. Filippatos,et al.  Empagliflozin and Major Renal Outcomes in Heart Failure. , 2021, New England Journal of Medicine.

[6]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[7]  P. Williamson,et al.  Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial , 2021, Nature Medicine.

[8]  H. Hung,et al.  The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials , 2021, Journal of clinical medicine.

[9]  M. Senni,et al.  Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. , 2021, Progress in cardiovascular diseases.

[10]  F. Cheema,et al.  Diuretic therapy in congestive heart failure , 2021, Acta cardiologica.

[11]  R. D. de Boer,et al.  Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC Focus Seminar. , 2021, Journal of the American College of Cardiology.

[12]  Yugang Dong,et al.  Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction , 2020, ESC heart failure.

[13]  Sanjiv J. Shah,et al.  Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. , 2020, JAMA.

[14]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[15]  I. Plastira,et al.  Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. , 2020, Pharmacological research.

[16]  R. Robinson,et al.  Heart Failure Drug Class Effects on 30-Day Readmission Rates in Patients with Heart Failure with Preserved Ejection Fraction: A Retrospective Single Center Study , 2020, Medicines.

[17]  W. Aronow.  Faculty Opinions recommendation of Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. , 2020 .

[18]  Zhuyin Li,et al.  Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. , 2020, JACC. Heart failure.

[19]  Sanjiv J. Shah,et al.  Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning , 2020, Heart.

[20]  Sanjiv J. Shah,et al.  Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. , 2019, Journal of the American College of Cardiology.

[21]  G. Raghu,et al.  Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis , 2019, European Respiratory Review.

[22]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[23]  R. Nishimura,et al.  Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial , 2019, Advances in Therapy.

[24]  C. Ayers,et al.  Phenomapping of patients with heart failure with preserved ejection fraction using machine learning‐based unsupervised cluster analysis , 2019, European journal of heart failure.

[25]  Sanjiv J. Shah,et al.  Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. , 2019, JAMA.

[26]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[27]  C. Reid,et al.  Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies , 2018, Cardiovascular research.

[28]  Gabriel A. Koepp,et al.  Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial , 2018, JAMA.

[29]  P. Dong,et al.  Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis , 2018, Journal of Human Hypertension.

[30]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[31]  D. Kitzman,et al.  Making the Case for Skeletal Muscle Myopathy and Its Contribution to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. , 2017, Circulation. Heart failure.

[32]  M. Matsuhisa,et al.  Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study , 2017, Cardiovascular Diabetology.

[33]  Wei Wu,et al.  The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway , 2017, Cellular Physiology and Biochemistry.

[34]  H. Ulmer,et al.  Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial). , 2017, Heart, lung & circulation.

[35]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of cardiac failure.

[36]  M. Senni,et al.  Addressing the Heterogeneity of Heart Failure in Future Randomized Trials , 2017, Current Heart Failure Reports.

[37]  G. Fonarow,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Circulation.

[38]  R. Coronel,et al.  Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits , 2016, Diabetologia.

[39]  S. Ulrich,et al.  Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction , 2016, Wiener klinische Wochenschrift.

[40]  J. Fang,et al.  Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder? , 2019, Current Hypertension Reports.

[41]  G. Lewis,et al.  Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. , 2016, Circulation. Heart failure.

[42]  Darren K Mcguire,et al.  Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus , 2016, Diabetes & vascular disease research.

[43]  R. Wachter,et al.  Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. , 2016, JACC. Heart failure.

[44]  W. Kraus,et al.  Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[45]  C. Cannon,et al.  Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[46]  M. Drazner,et al.  Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review , 2015, Journal of the American Heart Association.

[47]  S. Blankenberg,et al.  Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?". , 2015, World journal of cardiology.

[48]  U. A. Ndefo,et al.  Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes. , 2015, P & T : a peer-reviewed journal for formulary management.

[49]  K. Anstrom,et al.  A reappraisal of loop diuretic choice in heart failure patients. , 2015, American heart journal.

[50]  W. Edwards,et al.  Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[51]  Michael A. Burke,et al.  Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[52]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[53]  Ambarish Pandey,et al.  Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction: Meta-Analysis of Randomized Control Trials , 2014, Circulation. Heart failure.

[54]  L. Friberg,et al.  Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. , 2014, JAMA.

[55]  W. Kraus,et al.  Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. , 2014, American journal of physiology. Heart and circulatory physiology.

[56]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[57]  R. Wachter,et al.  RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. , 2013, JACC. Heart failure.

[58]  B. Chakraborty,et al.  Treating Anemia in Older Adults With Heart Failure With a Preserved Ejection Fraction With Epoetin Alfa: Single-blind Randomized Clinical Trial of Safety and Efficacy , 2013, Circulation. Heart failure.

[59]  R. Wachter,et al.  Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. , 2013, JAMA.

[60]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[61]  T. Akasaka,et al.  Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[62]  R. Arena,et al.  Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.

[63]  Rebekah A. Weaver,et al.  Impaired Heart Rate Recovery and Chronotropic Incompetence in Patients With Heart Failure With Preserved Ejection Fraction , 2009, Circulation. Heart failure.

[64]  V. Roger,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.

[65]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[66]  G. Tenderich,et al.  Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. , 2008, Journal of molecular and cellular cardiology.

[67]  N. Freemantle,et al.  FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .

[68]  Ann Marie Schmidt,et al.  Advanced glycation end products: sparking the development of diabetic vascular injury. , 2006, Circulation.

[69]  P. Poole‐Wilson,et al.  Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. , 2006, European heart journal.

[70]  W. Hundley,et al.  The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. , 2005, Journal of cardiac failure.

[71]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[72]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[73]  D. Brater.  Diuretic therapy in congestive heart failure. , 2000, Congestive heart failure.